{
    "organizations": [],
    "uuid": "4639ecb4bd4f012d9f37b9431a5e2278596ce492",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-adynxx-phase-2-results-of-brivolig/brief-adynxx-phase-2-results-of-brivoligide-for-treatment-of-post-surgical-pain-did-not-meet-primary-endpoint-idUSFWN1RP0N3",
    "ord_in_thread": 0,
    "title": "BRIEF-Adynxx - Phase 2 Results Of Brivoligide For Treatment Of Post Surgical Pain Did Not Meet Primary Endpoint",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 12 (Reuters) - ADYNXX:\n* ADYNXX - PHASE 2 STUDY RESULTS OF BRIVOLIGIDE (AYX1) FOR TREATMENT OF POST SURGICAL PAIN DID NOT MEET PRIMARY ENDPOINT Source text for Eikon: (Reuters.Briefs@thomsonreuters.com)\n ",
    "published": "2018-04-12T20:20:00.000+03:00",
    "crawled": "2018-04-13T17:31:34.012+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "adynxx",
        "adynxx",
        "phase",
        "study",
        "result",
        "brivoligide",
        "ayx1",
        "treatment",
        "post",
        "surgical",
        "pain",
        "meet",
        "primary",
        "endpoint",
        "source",
        "text",
        "eikon"
    ]
}